MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.520
-0.250
-6.63%
After Hours: 3.670 +0.15 +4.26% 17:02 07/10 EDT
OPEN
3.800
PREV CLOSE
3.770
HIGH
3.800
LOW
3.500
VOLUME
89.36K
TURNOVER
--
52 WEEK HIGH
4.140
52 WEEK LOW
1.443
MARKET CAP
95.78M
P/E (TTM)
25.40
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MDWD stock price target is 7.10 with a high estimate of 10.00 and a low estimate of 5.50.

EPS

MDWD News

More
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
GlobeNewswire · 06/30 12:00
MediWound Announces Submission Of Biologics License Application To The US FDA For NexoBrid For The Treatment Of Severe Thermal Burns
YAVNE, Israel, June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound
Benzinga · 06/30 11:09
Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers
Zacks · 05/27 15:29
4 Profitable Stocks to Boost Returns Using Net Income Ratio
Zacks · 05/26 13:16
MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/20 18:46
MediWound EPS beats by $0.05, beats on revenue
MediWound (NASDAQ:MDWD): Q1 GAAP EPS of -$0.09 beats by $0.05. Revenue of $4.44M (+865.2% Y/Y) beats by $0.39M. Press Release
seekingalpha · 05/20 16:07
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
Zacks · 05/20 13:15
Recap: MediWound Q1 Earnings
Benzinga · 05/20 12:13

Industry

Pharmaceuticals
-0.37%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About MDWD

MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
More

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.